Cynosure Inc (CYNO) 31.37 $CYNO
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AVP: 9.08 (+0.39), CYNO: 31.37 (+0.80), CS: 23.65 (+0.23), ATU: 25.51 (+0.35), CRK: 6.09 (+0.46)
Dermatology Devices Market worth $11,337.0 Million by 2019
M2 - Thu Feb 12, 8:19AM CST
"Major Players of Dermatology Devices Market are Cutera, Inc. (U.S.), Cynosure, Inc. (U.S.), Genesis Biosystems, Inc. (U.S.), HEINE Optotechnik GmbH & Co. KG (Germany), Lumenis Ltd. (Israel), Michelson Diagnostics (U.K.), PhotoMedex, Inc. (U.S.), and Solta Medical, Inc. (U.S.)"The report segments the global dermatology devices market on the basis of applications, products, and geographies. he report provides a granular understanding of the dermatology devices market.
CYNO: 31.37 (+0.80), LMNS: 10.80 (+0.57), PHMD: 1.68 (+0.04)
Cynosure Up 34.1% Since SmarTrend Uptrend Call (CYNO)
Comtex SmarTrend(R) - Tue Feb 10, 5:00PM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 4 months, Cynosure has returned 34.08% as of today's recent price of $30.65.
CYNO: 31.37 (+0.80)
Cynosure's (CYNO) CEO Mike Davin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 2:07PM CST
CYNO: 31.37 (+0.80)
Cynosure (CYNO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 7:55AM CST
CYNO: 31.37 (+0.80)
Cynosure posts 4Q profit
Automated Insights - Tue Feb 10, 7:36AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $23 million.
CYNO: 31.37 (+0.80)
Cynosure misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 7:02AM CST
CYNO: 31.37 (+0.80)
Cynosure Reports Record Quarterly Revenue of $86.3 Million for the Fourth Quarter of 2014
PR Newswire - Tue Feb 10, 7:00AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three and 12 months ended December 31, 2014.
CYNO: 31.37 (+0.80)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 90.57 (+0.93), TLM: 7.63 (-0.03), CYNO: 31.37 (+0.80), PCG: 54.06 (-1.14), KKR: 24.42 (+0.06), GWR: 94.92 (-0.19), CDW: 37.03 (+0.63), ALLT: 9.15 (+0.02), HOT: 78.55 (+0.67), SAVE: 79.32 (-0.80), NSP: 48.91 (+1.20), MWW: 6.00 (+0.11), ACM: 27.79 (+0.82), DF: 16.19 (-0.11), REGN: 402.40 (+0.66), KO: 41.99 (-0.18), MLM: 145.23 (+3.15), RAI: 71.86 (-1.23), HCP: 42.87 (+0.20), SEE: 46.05 (-0.16), ENTG: 13.50 (-0.15), TAP: 72.82 (-0.96), ALR: 43.40 (-0.40), HNT: 55.97 (-0.43), OMC: 77.56 (+1.09), IMN: 3.93 (+0.13), SALE: 16.41 (+0.13), NILE: 29.02 (+0.07), CVS: 102.63 (-0.37), SFUN: 6.74 (-0.01)
Cynosure to Participate in Leerink Global Healthcare Conference
PR Newswire - Mon Feb 09, 7:30AM CST
Cynosure, Inc. (NASDAQ: CYNO) today announced that Chairman and Chief Executive Officer Michael Davin and Tim Baker, the Company's President and Chief Financial Officer, will participate in the Leerink Global Healthcare Conference in New York City.
CYNO: 31.37 (+0.80)
Shares of CYNO Up 33.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:13AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 33.38% as of today's recent price of $30.49.
CYNO: 31.37 (+0.80)
Dermatology Devices Market by Diagnostic Devices, Treatment Devices & by Application - Global Forecast to 2019
M2 - Sat Jan 31, 12:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/rvkwfp/dermatology) has announced the addition of the "Dermatology Devices Market by Diagnostic Devices, Treatment Devices & by Application - Global Forecast to 2019" report to their offering. The global dermatology devices market is expected to reach $11.33 billion by 2019 from $6.57 billion in 2014, at a CAGR of 11.50% between 2014 and 2019 Dermatology devices assist in enhancing and improving the patient's skin conditions. With the use of dermatological devices such as dermatoscopes, microscopes, and imaging techniques, the dermatologists are able to identify the skin disorders at an early stage. Dermatology treatment devices are widely used for the treatment of various skin indications such as scars, psoriasis, acne, skin cancer, varicose veins, and pigment and vascular lesions. The hair removal application is one of the largest application segments of the global dermatology treatment devices market in 2014. The report provides a granular understanding of the dermatology devices market. This report segments the global dermatology devices market on the basis of applications, products, and geographies. The application segments included in this report are diagnostic and treatment applications. The diagnostic applications are further segmented into skin cancer diagnosis and other diagnostic applications; whereas, the treatment applications include hair removal, skin rejuvenation, pigmented lesions, vascular lesions, wrinkle removal, skin resurfacing, acne, psoriasis, tattoo removal, and other treatment applications. The product segments included in this report are diagnostic devices and treatment devices. The diagnostic devices segment includes dermatoscopes, microscope, and imaging techniques; while the treatment devices segment includes light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion, and cryotherapy devices. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Dermatology Diagnostic Devices Market, By Type 8 Dermatology Treatment Device Market, By Type 9 Dermatology Treatment Devices Market, By Application 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Alma Lasers, Ltd. - Bruker Corporation - Carl Zeiss - Cutera, Inc. - Cynosure, Inc. - Gen, Inc. - Genesis Biosystems, Inc. - Heine Optotechnik Gmbh & Co. Kg - Lumenis, Ltd. - Michelson Diagnostics, Ltd. - Photomedex, Inc. - Solta Medical, Inc. For more information visit http://www.researchandmarkets.com/research/rv...ermatology
CYNO: 31.37 (+0.80), LMNS: 10.80 (+0.57)
Cynosure Has Returned 34.3% Since SmarTrend Recommendation (CYNO)
Comtex SmarTrend(R) - Tue Jan 27, 9:48AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 34.27% as of today's recent price of $30.70.
CYNO: 31.37 (+0.80)
Cynosure reports February 10
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:36AM CST
CYNO: 31.37 (+0.80)
Cynosure To Host Fourth-Quarter 2014 Financial Results Conference Call On February 10
PR Newswire - Mon Jan 26, 8:40AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its fourth-quarter 2014 financial results before the market opens on Tuesday, February 10 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 31.37 (+0.80)
31.2% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Tue Jan 20, 9:21AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 31.23% as of today's recent price of $30.00.
CYNO: 31.37 (+0.80)
Cynosure Appoints William O. Flannery as Lead Director
PR Newswire - Tue Jan 13, 6:30AM CST
Cynosure, Inc. (NASDAQ: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company's independent directors have elected William O. Flannery as Lead Director. Flannery, a member of Cynosure's Board of Directors since June 2013, will continue to serve on the Compensation and the Nominating and Corporate Governance committees of the Board.
CYNO: 31.37 (+0.80)
Strength Seen in Cynosure (CYNO): Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:25AM CST
Cynosure (CYNO) was a big mover last session, with shares rising nearly 7% on the day.
ABMD: 60.39 (+0.46), CYNO: 31.37 (+0.80)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AVP: 9.08 (+0.39), CYNO: 31.37 (+0.80), CS: 23.65 (+0.23), ATU: 25.51 (+0.35), CRK: 6.09 (+0.46)
Dermatology Devices Market worth $11,337.0 Million by 2019
M2 - Thu Feb 12, 8:19AM CST
"Major Players of Dermatology Devices Market are Cutera, Inc. (U.S.), Cynosure, Inc. (U.S.), Genesis Biosystems, Inc. (U.S.), HEINE Optotechnik GmbH & Co. KG (Germany), Lumenis Ltd. (Israel), Michelson Diagnostics (U.K.), PhotoMedex, Inc. (U.S.), and Solta Medical, Inc. (U.S.)"The report segments the global dermatology devices market on the basis of applications, products, and geographies. he report provides a granular understanding of the dermatology devices market.
CYNO: 31.37 (+0.80), LMNS: 10.80 (+0.57), PHMD: 1.68 (+0.04)
Cynosure Up 34.1% Since SmarTrend Uptrend Call (CYNO)
Comtex SmarTrend(R) - Tue Feb 10, 5:00PM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 4 months, Cynosure has returned 34.08% as of today's recent price of $30.65.
CYNO: 31.37 (+0.80)
Cynosure's (CYNO) CEO Mike Davin on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 2:07PM CST
CYNO: 31.37 (+0.80)
Cynosure (CYNO) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 10, 7:55AM CST
CYNO: 31.37 (+0.80)
Cynosure posts 4Q profit
Automated Insights - Tue Feb 10, 7:36AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $23 million.
CYNO: 31.37 (+0.80)
Cynosure misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 7:02AM CST
CYNO: 31.37 (+0.80)
Cynosure Reports Record Quarterly Revenue of $86.3 Million for the Fourth Quarter of 2014
PR Newswire - Tue Feb 10, 7:00AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three and 12 months ended December 31, 2014.
CYNO: 31.37 (+0.80)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 4:30PM CST
WYN: 90.57 (+0.93), TLM: 7.63 (-0.03), CYNO: 31.37 (+0.80), PCG: 54.06 (-1.14), KKR: 24.42 (+0.06), GWR: 94.92 (-0.19), CDW: 37.03 (+0.63), ALLT: 9.15 (+0.02), HOT: 78.55 (+0.67), SAVE: 79.32 (-0.80), NSP: 48.91 (+1.20), MWW: 6.00 (+0.11), ACM: 27.79 (+0.82), DF: 16.19 (-0.11), REGN: 402.40 (+0.66), KO: 41.99 (-0.18), MLM: 145.23 (+3.15), RAI: 71.86 (-1.23), HCP: 42.87 (+0.20), SEE: 46.05 (-0.16), ENTG: 13.50 (-0.15), TAP: 72.82 (-0.96), ALR: 43.40 (-0.40), HNT: 55.97 (-0.43), OMC: 77.56 (+1.09), IMN: 3.93 (+0.13), SALE: 16.41 (+0.13), NILE: 29.02 (+0.07), CVS: 102.63 (-0.37), SFUN: 6.74 (-0.01)
Cynosure to Participate in Leerink Global Healthcare Conference
PR Newswire - Mon Feb 09, 7:30AM CST
Cynosure, Inc. (NASDAQ: CYNO) today announced that Chairman and Chief Executive Officer Michael Davin and Tim Baker, the Company's President and Chief Financial Officer, will participate in the Leerink Global Healthcare Conference in New York City.
CYNO: 31.37 (+0.80)
Shares of CYNO Up 33.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:13AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 33.38% as of today's recent price of $30.49.
CYNO: 31.37 (+0.80)
Dermatology Devices Market by Diagnostic Devices, Treatment Devices & by Application - Global Forecast to 2019
M2 - Sat Jan 31, 12:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/rvkwfp/dermatology) has announced the addition of the "Dermatology Devices Market by Diagnostic Devices, Treatment Devices & by Application - Global Forecast to 2019" report to their offering. The global dermatology devices market is expected to reach $11.33 billion by 2019 from $6.57 billion in 2014, at a CAGR of 11.50% between 2014 and 2019 Dermatology devices assist in enhancing and improving the patient's skin conditions. With the use of dermatological devices such as dermatoscopes, microscopes, and imaging techniques, the dermatologists are able to identify the skin disorders at an early stage. Dermatology treatment devices are widely used for the treatment of various skin indications such as scars, psoriasis, acne, skin cancer, varicose veins, and pigment and vascular lesions. The hair removal application is one of the largest application segments of the global dermatology treatment devices market in 2014. The report provides a granular understanding of the dermatology devices market. This report segments the global dermatology devices market on the basis of applications, products, and geographies. The application segments included in this report are diagnostic and treatment applications. The diagnostic applications are further segmented into skin cancer diagnosis and other diagnostic applications; whereas, the treatment applications include hair removal, skin rejuvenation, pigmented lesions, vascular lesions, wrinkle removal, skin resurfacing, acne, psoriasis, tattoo removal, and other treatment applications. The product segments included in this report are diagnostic devices and treatment devices. The diagnostic devices segment includes dermatoscopes, microscope, and imaging techniques; while the treatment devices segment includes light therapy devices, lasers, electrosurgical equipment, liposuction devices, microdermabrasion, and cryotherapy devices. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Dermatology Diagnostic Devices Market, By Type 8 Dermatology Treatment Device Market, By Type 9 Dermatology Treatment Devices Market, By Application 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Alma Lasers, Ltd. - Bruker Corporation - Carl Zeiss - Cutera, Inc. - Cynosure, Inc. - Gen, Inc. - Genesis Biosystems, Inc. - Heine Optotechnik Gmbh & Co. Kg - Lumenis, Ltd. - Michelson Diagnostics, Ltd. - Photomedex, Inc. - Solta Medical, Inc. For more information visit http://www.researchandmarkets.com/research/rv...ermatology
CYNO: 31.37 (+0.80), LMNS: 10.80 (+0.57)
Cynosure Has Returned 34.3% Since SmarTrend Recommendation (CYNO)
Comtex SmarTrend(R) - Tue Jan 27, 9:48AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 34.27% as of today's recent price of $30.70.
CYNO: 31.37 (+0.80)
Cynosure reports February 10
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:36AM CST
CYNO: 31.37 (+0.80)
Cynosure To Host Fourth-Quarter 2014 Financial Results Conference Call On February 10
PR Newswire - Mon Jan 26, 8:40AM CST
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its fourth-quarter 2014 financial results before the market opens on Tuesday, February 10 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 31.37 (+0.80)
31.2% Return Seen to Date on SmarTrend Cynosure Call (CYNO)
Comtex SmarTrend(R) - Tue Jan 20, 9:21AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on October 28th, 2014 at $22.86. In approximately 3 months, Cynosure has returned 31.23% as of today's recent price of $30.00.
CYNO: 31.37 (+0.80)
Cynosure Appoints William O. Flannery as Lead Director
PR Newswire - Tue Jan 13, 6:30AM CST
Cynosure, Inc. (NASDAQ: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company's independent directors have elected William O. Flannery as Lead Director. Flannery, a member of Cynosure's Board of Directors since June 2013, will continue to serve on the Compensation and the Nominating and Corporate Governance committees of the Board.
CYNO: 31.37 (+0.80)
Strength Seen in Cynosure (CYNO): Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 8:25AM CST
Cynosure (CYNO) was a big mover last session, with shares rising nearly 7% on the day.
ABMD: 60.39 (+0.46), CYNO: 31.37 (+0.80)
